Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #7 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited (this stock) | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 4,031 | 766 | 574 | ₹ |
| March 31, 2026 | 3,443 | 656 | 559 | ₹ |
| Dec. 31, 2025 | 3,567 | 506 | 414 | ₹ |
| Sept. 30, 2025 | 3,697 | 622 | 520 | ₹ |
| June 30, 2025 | 3,570 | 537 | 445 | ₹ |
| March 31, 2025 | 3,079 | 513 | 425 | ₹ |
| Dec. 31, 2024 | 3,230 | 494 | 385 | ₹ |
| Sept. 30, 2024 | 3,077 | 847 | 659 | ₹ |
| June 30, 2024 | 2,893 | 664 | 543 | ₹ |
| March 31, 2024 | 2,441 | 569 | 477 | ₹ |
| Dec. 31, 2023 | 2,607 | 558 | 460 | ₹ |
| Sept. 30, 2023 | 2,708 | 638 | 511 | ₹ |
| June 30, 2023 | 2,579 | 620 | 494 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 14,278 | 2,321 | 1,938 |
| March 31, 2025 | 12,207 | 2,504 | 2,011 |
| March 31, 2024 | 10,335 | 2,384 | 1,942 |
| March 31, 2023 | 8,749 | 1,659 | 1,310 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 3,121 | -196 | -2,953 | 626 | 2,495 |
| March 31, 2025 | 2,413 | -12,683 | 10,290 | 461 | 1,953 |
| March 31, 2024 | 2,152 | -2,082 | 5 | 315 | 1,837 |
| March 31, 2023 | 1,813 | -1,054 | -740 | 789 | 1,024 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 28,080 | 16,561 | 16,259 | 3,419 | 2,893 | 7,140 | 6,507 | 392 | 2,960 | 2,144 |
| March 31, 2025 | 27,760 | 14,568 | 14,291 | 2,971 | 5,540 | 7,175 | 5,664 | 407 | 2,908 | 2,094 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
